Highlights of headache and migraine research in 2016 was published on MedScape.com by Dr. Hans-Christoph Diener of University of Essen, Germany. He writes on the latest in complications of migraines, triptans and botulinum toxin. Most exciting is the latest in supressing calcitonin gene-related peptides.
The biggest progress in migraine and cluster headache will be the use of antibodies against calcitonin gene-related peptides (CGRP), either against a molecule or the receptor. Phase 2 trials in episodic migraine and chronic migraine were published. The responder rate, defined as a reduction of migraine frequency of at least 50%, was achieved by one half of the patients. The most important issue here is safety and tolerability: The tolerability has been excellent. and there have basically been almost no side effects. All of these drugs are now in phase 3 randomized trials for episodic and chronic migraine, but also for episodic and chronic cluster headache. Hopefully, next year I will be able to tell you how effective and well tolerated these new drugs are.
Source article here.